文献速递毛发、甲与色素性疾病皮肤肿瘤

持续性化疗后脱发的患者生活质量与治疗结局评估

Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
PubMed 文献 · JAMA Dermatol · 2019-01-01

这项多中心回顾性队列研究分析了192例接受细胞毒性药物治疗后出现持续性脱发的女性癌症患者,其中98例为持续性化疗诱导脱发(pCIA),94例为化疗后内分泌治疗诱导脱发(EIAC)。局部米诺地尔或螺内酯治疗后,pCIA组67%(36/54)和EIAC组76%(32/42)获得中度至显著改善。

要点

  • pCIA较EIAC更常表现为弥漫性脱发且严重程度更高。
  • 两组患者均报告脱发带来负面情绪影响。
  • 局部米诺地尔或螺内酯治疗仅见适度获益。

核心结论

  • 持续性化疗诱导脱发较化疗后内分泌治疗诱导脱发更严重且更弥漫,两组均受负面情绪影响,皮肤科治疗获益有限。

研究设计与样本

  • 回顾性多中心队列研究,纳入2009年1月1日至2017年7月31日期间2个综合癌症中心和1个三级医院的192例接受细胞毒性药物治疗后临床诊断为持续性脱发的女性癌症患者(98例pCIA,94例EIAC)。

主要发现

  • pCIA组最常见相关药物为紫杉类(80例,82%),EIAC组最常见为芳香化酶抑制剂(58例,62%)。
  • 局部米诺地尔或螺内酯治疗后,pCIA组36/54(67%)和EIAC组32/42(76%)获得中度至显著改善。

临床怎么用

  • 对接受紫杉类或芳香化酶抑制剂治疗后的女性癌症患者,应评估持续性脱发及其生活质量影响。
  • 局部米诺地尔或螺内酯可作为持续性脱发的治疗选择,但需告知患者获益可能有限。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 样本仅来自2个综合癌症中心和1个三级医院,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Persistent alopecia occurs in a subset of patients undergoing chemotherapy, yet the quality of life (QOL) of these patients and their response to therapy have not been described in a large patient cohort. OBJECTIVE: To characterize the clinical presentation of patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia after chemotherapy (EIAC) and their QOL and treatment outcomes. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter cohort of 192 women with cancer treated with cytotoxic agents who received a clinical diagnosis of persistent alopecia (98 with pCIA and 94 with EIAC) between January 1, 2009, and July 31, 2017, was analyzed. All patients were from the dermatology service in 2 comprehensive cancer centers and 1 tertiary-care hospital. Data on demographics, chemotherapy regimens, severity, clinical patterns, and response to hair-growth promoting agents were assessed. Data from the Hairdex questionnaire were used to assess the QOL of patients with alopecia. MAIN OUTCOMES AND MEASURES: The clinical presentation, response to dermatologic therapy, and QOL of patients with pCIA were assessed and compared with those of patients with EIAC. RESULTS: A total of 98 women with pCIA (median age, 56.5 years [range, 18-83 years]) and 94 women with EIAC (median age, 56 years [range, 29-84 years]) were included. The most common agents associated with pCIA were taxanes for 80 patients (82%); the most common agents associated with EIAC were aromatase inhibitors for 58 patients (62%). Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = .04), with greater severity (Common Terminology Criteria for Adverse Events, version 4.0, grade 2) among patients with pCIA (29 of 75 [39%] vs 12 of 92 [13%]; P < .001). A negative emotional effect was reported by both groups. After treatment with topical minoxidil or spironolactone, moderate to significant improvement was observed for 36 of 54 patients with pCIA (67%) and for 32 of 42 patients with EIAC (76%). CONCLUSIONS AND RELEVANCE: Persistent chemotherapy-induced alopecia is frequently more severe and diffuse when compared with EIAC, and both groups of patients experienced a negative effect. A modest benefit was observed with dermatologic therapy. Additional studies are warranted to develop effective strategies for prevention and effective therapy for pCIA and EIAC.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. JAMA Dermatol. 2019. PMID: 30840033. doi:10.1001/jamadermatol.2018.5071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。